The burden of Hepatitis B and C virus infections in patients with sickle cell anaemia in Jos – Nigeria by Egesie, O.J. et al.
100
ABSTRACT
ickle cell anaemia (SCA) is an inherited chronic 
haemolytic anaemia and the most common S
1, 2
heritable haematologic disease affecting humans.   
The chronic nature of the anaemia as a result of the 
unique pathologic defect has made blood transfusion a 
critical component of its management.
Blood transfusion is however associated with risk of 
contracting transfusion transmissible infections (TTIs) 
such as hepatitis B virus (HBV), hepatitis C virus 
(HCV), and human immunodeficiency viral infection 
 2
amongst others.
Research has estimated that approximately 8% of 
African Americans carry the sickle cell gene and about 
0.15% are homozygous (HbSS) resulting in sickle cell 
3
anaemia with its attendant morbidity and mortality.  
Nigeria has a sickle cell anaemia prevalence rate of 1-
3% and is considered to be among countries with the 
highest population of patients with this disease in the 
4,5
World.  It has been reported that twenty four percent 
of Nigerians are carriers of the sickle cell gene resulting 
in the birth of about 150,000 children with sickle cell 
4,5
anaemia annually.  A sizeable proportion of the 
children born with the disease are at risk of receiving 
blood transfusion. Furthermore, the complications 
associated with sickle cell anaemia, such as haemolytic, 
aplastic and sequestration crises increase the demand 
for blood transfusion in the care of these patients. These 
also increase their susceptibility to contracting TTIs.
The incidence of TTIs has been on the downward trend 
in recent years due to more effective donor screening 
INTRODUCTION
BACKGROUND: Sickle cell anaemia (SCA) is an important public health problem in Nigeria associated with 
frequent blood transfusion. Patients with this disease are at increased risk of contracting hepatitis B and C virus 
through blood transfusions.
OBJECTIVE:  The study aimed at determining the burden of hepatitis B and C virus infections in patients with 
sickle cell anaemia and the role of blood transfusion in these infections acquisition in Jos.
MATERIALS AND METHODS:  This was an observational cross-sectional study conducted on patients with 
SCA attending the Haematology Out-patient Clinic of Jos University Teaching Hospital, between November 2014 
and August 2015. Consenting patients with SCA had their blood screened for anti- HBV and HCV antibodies using 
fourth generation Elisa techniques after completing a questionnaire.
RESULTS: One hundred and eleven patients with SCA participated.  Antibodies to Hepatitis B virus (HBV) was 
detected in 21 (18.9%) while that to Hepatitis C virus (HCV) was found in 16 (14.7%). Seventy six (68.5%) of the 
participants had history of blood transfusion while 35 (31.5%) were never transfused. 22.4% and 15.8% of those 
transfused were positive for HBV and HCV antibodies respectively. There was no significant difference in the 
proportion of those positive for anti HBV or HCV with respect to their transfusion status (p=0.24 and 0.81 
respectively).
CONCLUSION:  The proportion of our patients with SCA that were anti HBV and anti-HCV positive was high. 
Blood transfusion did not significantly influence their positive status. Strategies aimed at controlling these viral 
infections in these patients and the general population should be enforced after public awareness campaigns and 
advocacy are instituted. 
KEYWORDS: Sickle Cell Anaemia, burden, Hepatitis B Virus, Hepatitis C Virus, infection, Blood Transfusion.
Corresponding Author:   Dr. Ezra D Jatau
Department of Haematology and Blood Transfusion, 
Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
Email: ezradjatau@gmail.com 
Tel: +234 8065403375
THE BURDEN OF HEPATITIS B AND C VIRUS INFECTIONS IN 
PATIENTS WITH SICKLE CELL ANAEMIA IN JOS – NIGERIA
 Egesie , Jatau , Damulak , Okeke , Zakari , Jasini , Akinola , 
 Adeyemi , Akor , Egesie 
1 1 1 1 1 1 1
OJ ED OD CN A J OI
1 1 2O E UG
1
Department of Haematology and Blood Transfusion, Jos University Teaching Hospital, Jos, Nigeria.
2
Department of Human Physiology, Faculty of Medical Sciences, University of Jos, Nigeria
Original Article 
Nigerian Journal of Medicine, Vol. 26 No. 1, January - March, 2017, ISSN 1115-2613
NigerJMed2017: 41-46 
” 2017. Nigerian Journal of Medicine
41
Parameters                                                                                                              Frequency (%)                                    
Mean age (years)                  25.6±6.7
Sex  
      
Male                                                                                                                    48 (43.2)
Female                                                                                                                63 (56.8)
                                         
      Marital Status 
 
      
Single                                                                                            
                     
90 (81.1)
      
Married                                                                                                16 (14.4)
      
Separated                                                                             
                              
3 (2.7)
      
Divorced                                                                                               1 (0.9)
Widow                                                                            1 (0.9)
Transfusion status
 
      
Transfused                                                                                                        76 (68.5)
Not Transfused                                            35 (30.0)
Mean number of units transfused                                   2.81 ± 2.75
ANALYSIS OF DATA
 Statistical analysis of data obtained from the study was 
done using EPI INFO version 7.1.3.0 (CDC Atlanta 
Georgia, USA). Results were presented in tables and 
graphs while chi-square and students' t-test were used 
to assess significant differences. Results with p-values 
< 0.05 was considered statistically significant.
RESULTS
One hundred and eleven (111) patients with sickle cell 
anaemia were studied. Forty-eight (43.2%) were males 
while 63 (56.8%) were females giving a Male: Female 
ratio of 1:1.3 (Table 1).The mean age of participants was 
25.6 ± 6.7 years and an age range of 17-52 years. 
Majority (81.0%) of the participants were unmarried 
and aged between 20-34 years (Figure 1)
History of blood transfusion was recorded in 76 (68.5%) 
of the participants while 35 (31.5%) were never 
transfused. Amongst the participants transfused, 29 
(38.2%) were males and 47 (61.8%) were females. Sixty-
eight (68) of those transfused were able to recall the 
number of units they received at different times 
ranging from 1 to 20 units with a mean transfusion of 
2.81± 2.75 units (Table 1).
methods, though the risk of acquiring TTIs is yet to be 
6-8
completely eradicated. 
This is more profound in resource-constraint setting 
like ours with technical, economic and infrastructural 
9-11
challenges.  Studies have reported a higher 
prevalence rate of HBV and HCV infection in patients 
12, 13
with SCD than the general population.  The higher 
rate of HCV infection in patients with SCD was 
attributed to the late introduction of HCV donor 
14 
screening in 1992. 
Studies have also indicated increased risk of 
development of hepatocellular carcinoma and chronic 
liver disease in multi-transfused individuals due to 
transfusion-related acquisition of HBV and HCV 
15, 16
infection. 
This study aimed at determining the burden of HBV 
and HCV infections in our patients with SCA, it also 
investigated the role of blood transfusion in the 
acquisition of these viral infections in these patients 
and assessed the effectiveness or otherwise, of pre-
donation screening methods used in the prevention of 
transfusion acquired HBV and HCV infection from this 
Centre.
MATERIALS AND METHODS
We conducted a cross sectional study at the 
Haematology Out-Patient Clinic (HOPC) of the Jos 
University Teaching Hospital (JUTH), Jos between 
November 2014 and August 2015. Ethical approval was 
obtained from the Human Research and Ethics 
Committee of JUTH. 
Consenting adults with SCA attending the HOPC of 
JUTH were enrolled for the study. Non-consenting 
patients and other forms of anaemia and haematologic 
diseases were excluded.
Informed written consent was obtained from all the 
participants prior to the research procedure while 
maintaining strict confidentiality. Using a structured 
pre-tested questionnaire, personal data such as age, 
sex, marital status, history of blood transfusion, where 
transfused and number of units of blood received was 
obtained from each participant.
Participants had their blood samples collected and 
their haemoglobin electrophoresis determined using 
the cellulose acetate haemoglobin electrophoresis 
method at alkaline pH of 8.9 to confirm their sickle cell 
status. They were then screened for antibodies to 
Hepatitis B virus (HBV) and Hepatitis C virus (HCV) 
us ing  the  four th  genera t ion  ELISA k i t s ,  
(GENSCREENTM Bio-Rad, Marnes-la-Coquette, 
France).
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Table 1- Socio-demographic Characteristics, 
transfusion, HBV and HCV status of adults with SCA 
studied at the Jos University Teaching Hospital, 
Nigeria between November 2014 and August 2015    
(n =111) 
Viral antibody status          Number of units of blood transfused; n (%)                    p value
None                      <  10                      ≥10
HBV: Positive         4(11.4)                   14(21.5)                     1(50)                     0.24      
         Negative               31(88.6)                  51(78.5)                     1(50)
HCV: Positive        4(11.4)                    9(13.8)                          - 0.81
         
Negative             
   
31(88.6)                
  
56(86.2)              2(100)
                              
Figure 1. Age and sex distribution of adults with SCA 
studied at the Jos University Teaching Hospital, 
Nigeria between November 2014 and August 2015
(n =111)
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HCV Status  
      
Positive
                                                                                               
16 (14.7)                                                                                                                  
Negative                                                                                     95 (85.3)                                                                                            
                                                           
                                         
HBV Status
 
Positive                                            21 (18.9)                                                                                                     
Negative                                                          90 (81.1)                                                                                                              
Antibodies to Hepatitis B virus (HBV) was detected in 
21 (18.9%) of the 111 participants comprising of 17 
(81.0%) transfused and 4 (19%) non-transfused. 22.4% 
of the transfused patients with SCA were positive for 
HBV antibody.  Hepatitis C virus (HCV) antibodies 
was found in 16 (14.7%) of the participants, of which 12 
(75%) had blood transfusion while 4 (25%) had no 
history of blood transfusion. This implied that 15.8% 
(12/76) of those that had blood transfusion were HCV 
antibody positive. There was no significant difference 
in the proportion of those that tested positive to anti 
HBV or HCV antibodies for those transfused and non-
transfused. The number of units of blood received had 
no influence on their viral antibody status.  (Table 2). 
61.9% and 50% of those positive for HBV and HCV 
antibodies respectively were females. This may be 
related to the number of female patients that 
participated in this study.
Table 2. Blood transfusion rate, Hepatitis B and 
Hepatitis C virus antibody status of adults with SCA 
studied at the Jos University Teaching Hospital, 
Nigeria between 2014 and 2015 (n =111)
DISCUSSION
Patients with sickle cell anaemia are generally 
predisposed to various systemic complications 
necessitating blood transfusion due to the sickling and 
vaso-occlusive phenomena associated with the disease. 
They are therefore at risk of viral hepatitis from the 
multiple blood transfusions they often receive for their 
medical care. The risk for acquisition of transfusion-
related infections vary from one setting to the other 
depending on a number of factors such as availability 
of facilities for effective screening of blood and blood 
products, as well as trained laboratory personnel.  
The proportion of SCA patients positive for anti-HBV 
and anti-HCV antibodies in this study was 18.9% and 
14.7% respectively. This was high compared to the 
finding of Khan et al and Asma et al in similar group of 
17, 18
patients in Saudi Arabia and Turkey respectively.  It 
was also higher than the findings of Pennap et al in a 
community of apparently healthy individuals in Keffi, 
19
North-Central Nigeria.  This high burden of HBV and 
HCV infections in our SCA patients may be due to their 
exposure to blood transfusion, an established risk for 
transmission.
The finding of high anti-HBV in our patients was 
however similar to the findings of Egah et al and 
Adekeye et al in blood donors in Jos. They found a 
prevalence of 15.1% and 20.8% respectively for anti-
HBV but a lower anti-HCV prevalence of 4.3% and 
20,21
4.9% respectively.  Several researchers have reported 
varying seroprevalence of hepatitis infections among 
patients with SCA. This ranged from 3.0% to 39.0% for 
22-24
HBV and 4.5% to 21.0% for HCV.  The difference in 
these findings may be connected with the 
seroprevalence of these viral hepatitis among the 
general population in that region.
In relation to blood transfusion, those transfused had a 
seroprevalence of 22.4% (17/76) for anti HBV and 
15.8% (12/76) for anti HCV while those that never had 
blood transfusion had a seroprevalence of 11.4% (4/35) 
for both HBV and HCV. There was no significant 
difference between the transfused and non-transfused 
in this respect (p>0.05). 
The seroprevalence of HBV and HCV in the transfused 
was higher than the non-transfused in this study, 
although no statistical significant difference was found. 
This seemed to have demonstrated clearly the risk of 
acquiring the hepatitis viral infections through blood 
transfusion. SCA patients being more vulnerable are 
likely to receive multiple blood transfusions which put 
them at increased risk of acquiring these hepatitis viral 
infections. However, additional risk factors may have 
contributed to the high HCV burden in our non-
transfused SCA patients as previous studies reported 
lower HCV prevalence in blood donors from this 
 20, 21  
Centre.
The finding in this study of a higher seroprevalence of 
HCV in transfused SCA patients compared to 
prevalence of HCV in blood donors in previous study 
from this Centre, differed from a report by Adewuyi in 
Ilorin, Nigeria that did not find a significant difference 
in HCV prevalence between the multi-transfused sickle 
25 
cell patients and regular blood donors. 
The proportion of our transfused SCA patients who 
tested positive to anti HBV and HCV antibodies was 
however lower than that documented in a study by 
Fasola and Otegbayi in Ibadan Nigeria, but higher than 
that reported in a study done in Ahvaz, South Western 
Iran and another study in Western Odisha, India. 
Ibadan study reported 23.6% and 19.8% for anti-HBV 
and anti HCV respectively, Iranian study reported 
1.8%  and 12.5% for anti HBV and anti HCV 
respectively while the Indian study documented 2.9% 
26-28 
for HBV and  1.7% for HCV. 
The lower prevalence of anti HBV seen in Al-Ahsa and 
Odisha may not be unconnected with the advent of 
HBV vaccine and its use amongst the population in that 
region. This is unlike HCV whose vaccine is not yet 
available and donor screening for it only became 
14 
mandatory in 1992. 
Reports from Western Europe and North America have 
shown that the prevalence of Hepatitis B virus infection 
has fallen to less than 1%  among the general 
population after the introduction of its vaccine though 
it still remained as high as 10% in the developing 
 29
countries.   
Contrary to the finding in our study, several 
researchers have reported increasing seroprevalence of 
these viral infections with increasing number of blood 
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22-24
transfusion units received.  This calls for concerted 
effort in implementing all preventive measures against 
transfusion transmissible infection by improving blood 
transfusion protocol and their safety.
Although our study did not find any statistical 
difference between the transfused and non-transfused 
participants in association with HBV and HCV positive 
status, the high burden of these viral infections among 
transfused sickle cell anemia patients calls for concern 
and deliberate efforts targeted at reduction of these 
infections. 
In this study, 84.4% of our patients had history of blood 
transfusion. This was similar to findings from 
30-32
elsewhere.  This confirmed the fact that SCA patients 
are prone to receiving blood transfusion due to the 
complications associated with the disease such as 
hyperhaemolytic, sequestration and aplastic crises.
There was no statistically significant difference in 
either anti-HBV or anti-HCV positive status between 
males and females in this study (p = 0.59 and 0.56 
respectively). Statistical significant association was not 
also established between age groups, marital status 
and HBV and HCV positive status despite the fact that 
significant population of the participants (81.0%) were 
unmarried and aged between 20-34 years (p>0.05). This 
seems to support the fact that blood transfusion may be 
the most important risk factor for the acquisition of 
these viral infections in these patients with SCA. This 
calls for strategies aimed at further improving the 
safety of local blood supply through increased 
awareness of donating blood voluntarily.  
CONCLUSION
The burden of HBV and HCV in our patients with SCA 
from this Centre is high. Blood transfusion is a vital 
component in the management of sickle cell anaemia 
and with this management modality comes the 
complication of HBV and HCV infections. Although 
the study did not show a significant role played by 
blood transfusion in the acquisition of HBV and HCV 
infections in our patients, there is still need for 
concerted effort in implementing all preventive 
measures against transfusion transmissible infections 
by improving blood transfusion protocol and their 
safety. Measures such as detection of viral genome in 
potential blood donors should be part of the panel of 
pre-donation tests for intending blood donors. Public 
enlightenment campaigns as well as vaccinations 
against HBV now and HCV when available should be 
made routine for all SCA patients and enforced in the 
general population to reduce these infections.
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